COMMITTEE ON HEALTH, HOSPITALS AND HUMAN SERVICES

BILL NO. 35-0207

Thirty-Fifth Legislature of the Virgin Islands

December 11, 2023

An Act amending title 19 Virgin Islands Code, part I, adding chapter 6a to create the Territorial Chronic Kidney Disease and Diabetes Registry

PROPOSED BY: Senator Ray Fonseca

1 Be it enacted by the Legislature of the Virgin Islands:

2 SECTION 1. Title 19 Virgin Islands Code, part I, is amended by adding a chapter 6a

3 that reads as follows:

4 "Chapter 6a. Territorial Chronic Kidney Disease and Diabetes Registry

5 § 121. Definitions

6 As used in this chapter:

7 (a) "Health care facility" means hospitals; health care clinics; health centers; skilled
8 nursing facilities; mental health facilities; kidney disease treatment centers, including
9 freestanding hemodialysis units; intermediate care facilities; ambulatory surgical facilities;
10 rehabilitation facilities; health maintenance organizations; and hospice care facilities.

(b) "Health care provider" means a person, corporation, facility or institution licensedin the Territory to provide health care or professional, medical services including a medical,

1	osteopathic, chiropractic or naturopathic physician; hospital; dentist; registered nurse,
2	including an advanced practice registered nurse; optometrist; podiatrist; physical therapist;
3	psychologist; pharmacist and laboratory technician.
4	(c) "Individually identifiable health information" means information that is a subset of
5	health information, including demographic information collected from an individual, and:
6	(1) is created or received by a health care provider, health plan, employer, or
7	health care clearinghouse;
8	(2) relates to the past, present, or future physical or mental health or condition
9	of an individual; the provision of health care to an individual; or the past, present or future
10	payment for the provision of health care to an individual; and
11	(3) identifies the individual:
12	(A) by such common identifiers as name, address, birth date, social
13	security number and other common identifies, or
14	(B) with respect to which there is a reasonable basis to believe the
15	information can be used to identify the individual.
16	(d) "Registry" means the Territorial Chronic Kidney Disease and Diabetes Registry.
17	(e) "Reporting entity" means a healthcare facility that provides services to individuals
18	who are diabetic and/or have chronic kidney disease and those receiving dialysis treatments.
19	(f) "Territory" means the Virgin Islands of the United States.
20	§ 122. Establishment of the Territorial Chronic Kidney Disease and Diabetes Registry
21	(a) There is established within the Department of Health, the Territorial Chronic
22	Kidney Disease and Diabetes Registry. The Registry serves as the territorial surveillance
23	system and repository of data regarding patients who have been diagnosed with chronic kidney

1	disease, patients who are receiving dialysis, and patients diagnosed with diabetes in the
2	Territory.
3	(b) The data concerning each case of diabetes is to be collected and used to conduct
4	epidemiological surveys of diabetes cases in this Territory. The data collected must include:
5	(1) an individual's date of diagnosis;
6	(2) age at time of diagnosis;
7	(3) the type of diabetes that was diagnosed;
8	(4) whether the individual has a known history of any type of diabetes in the
9	individual's family;
10	(5) the individual's height and weight, and
11	(6) the individual's sex, race, ethnicity, and residential address.
12	(c) The data concerning each person with chronic kidney disease is to be collected and
13	used to conduct epidemiological surveys of chronic kidney disease cases in this territory. The
13 14	used to conduct epidemiological surveys of chronic kidney disease cases in this territory. The data collected must include:
14	data collected must include:
14 15	data collected must include: (1) the patient's height, weight, medical history, diet, and lifestyle;
14 15 16	 data collected must include: (1) the patient's height, weight, medical history, diet, and lifestyle; (2) the patient's sex, race, ethnicity, and residential address;
14 15 16 17	 data collected must include: (1) the patient's height, weight, medical history, diet, and lifestyle; (2) the patient's sex, race, ethnicity, and residential address; (3) kidney disease stage (1-early, 2-mild, 3-moderate, 4-severe, 5-end stage), and
14 15 16 17 18	 data collected must include: (1) the patient's height, weight, medical history, diet, and lifestyle; (2) the patient's sex, race, ethnicity, and residential address; (3) kidney disease stage (1-early, 2-mild, 3-moderate, 4-severe, 5-end stage), and information about related comorbidities such as heart disease, hypertension, and diabetes;
14 15 16 17 18 19	 data collected must include: (1) the patient's height, weight, medical history, diet, and lifestyle; (2) the patient's sex, race, ethnicity, and residential address; (3) kidney disease stage (1-early, 2-mild, 3-moderate, 4-severe, 5-end stage), and information about related comorbidities such as heart disease, hypertension, and diabetes; (4) the total number of patients on dialysis, per each island, and whether the
14 15 16 17 18 19 20	 data collected must include: (1) the patient's height, weight, medical history, diet, and lifestyle; (2) the patient's sex, race, ethnicity, and residential address; (3) kidney disease stage (1-early, 2-mild, 3-moderate, 4-severe, 5-end stage), and information about related comorbidities such as heart disease, hypertension, and diabetes; (4) the total number of patients on dialysis, per each island, and whether the patient is receiving hemodialysis or peritoneal dialysis;
14 15 16 17 18 19 20 21	 data collected must include: (1) the patient's height, weight, medical history, diet, and lifestyle; (2) the patient's sex, race, ethnicity, and residential address; (3) kidney disease stage (1-early, 2-mild, 3-moderate, 4-severe, 5-end stage), and information about related comorbidities such as heart disease, hypertension, and diabetes; (4) the total number of patients on dialysis, per each island, and whether the patient is receiving hemodialysis or peritoneal dialysis; (5) laboratory values for diagnostic tests, and medications;

- 1
- (8) kidney transplant candidates; and
- 2 (9) the location of healthcare facilities and healthcare providers that offer dialysis
 3 services.
- 4 (d) The Registry shall train and certify personnel designated by the reporting entities
 5 as persons responsible for reporting information to the Registry.

6 (e) The Commissioner of Health shall promulgate administrative guidelines as may
7 be amended from time to time to ensure that the Registry performs its mandate.

8

§ 123. Participation in the program

9 (a) Within 60 days of the enactment of this act, the Registry shall create a standardized 10 form for each healthcare provider and health care facility to use to submit all reportable data. 11 Each healthcare provider and health care facility shall report in an electronic format, or any 12 other format requested by the Registry each new case of diabetes and chronic kidney disease 13 to the Registry not later than 180 days after the date of diagnosis or date of first contact with 14 the already diagnosed patient.

15 § 124. Confidentiality

(a) All chronic kidney disease and diabetes data provided to the Registry must be
kept confidential. No information reported to the Registry which identifies or could lead to the
identification of an individual patient may be disclosed to any person or entity; except that the
identifying information may be disclosed to another state chronic kidney disease and diabetes
registry and territorial health officers.

(b) State chronic kidney disease and diabetes registries, chronic kidney disease and
diabetes researchers or federal chronic kidney disease and diabetes control agencies that receive
chronic kidney disease and diabetes case data from the Registry shall enter into an agreement
with the Registry to keep the information confidential.

(c) All Registry employees and researchers shall sign a confidentiality agreement.
 These agreements remain effective after the employee or researcher no longer has a relationship
 with the Registry, and will expire after two years.

4 § 125. Disclosure

5 (a) Chronic kidney disease and diabetes case data may be shared with chronic kidney 6 disease and diabetes researchers or Federal chronic kidney disease and diabetes control 7 agencies for the purposes of chronic kidney disease and diabetes prevention, control, and 8 research upon the submittal of documentation to the Registry providing that research in chronic 9 kidney disease and diabetes prevention or control is ongoing or approval for such research has 10 been granted. If applicable, the Registry shall also request evidence of compliance with the 11 requirements of 45 CFR Part 46: Protection of Human Subjects.

(b) The Registry may share statistical compilations of the chronic kidney disease and
diabetes case data with state chronic kidney disease and diabetes registries and Federal chronic
kidney disease and diabetes control agencies for the following reasons:

15 (1) to perform studies on the sources and causes of chronic kidney disease and
16 diabetes;

17 (2) to track the changing patterns of chronic kidney disease and diabetes
18 incidences;

19 (3) to provide patient education and support, individualized to patients' stage of
20 disease and related health conditions;

(4) to create a robust database of patient outcomes, perceptions, priorities and
 activities that will facilitate research, clinical care and policy decisions to improve
 patients' experience and outcomes; and

5

(5) for any other clinical, epidemiological, or other chronic kidney disease and
 diabetes research.

3 § 126. Liability

4 (a) No person, who in good faith, discloses privileged or confidential information or
5 provides chronic kidney disease and diabetes case reports to the Registry or allows the Registry
6 access to a chronic kidney disease and diabetes case report is liable in any civil action.

7 (b) The license of a health care provider or a health care facility may not be
8 suspended or revoked for the disclosure of information provided to the Registry pursuant to
9 this chapter.

10 (c) The protection from liability provided in subsection (a) and (b) does not apply to
11 the unauthorized disclosure of confidential or privileged information when the disclosure is due
12 to gross negligence or willful misconduct.

13 § **127.** Penalties

Any person who violates a reporting provision of this chapter or regulations or orders 14 pertaining to the reporting of information to the Registry is subject to a civil fine of not less 15 16 than \$1,000 per case but not more than \$5,000 per case. Before assessing the fine, the Commissioner of Health, or the Commissioner's designee, shall conduct a hearing with the 17 person or entity to ascertain the reason for noncompliance and determine if an adjustment in 18 the fine is warranted. Funds collected pursuant to this subsection must be deposited in an 19 account established by the Department of Health within the Department of Finance. The 20 monies in this account must be used exclusively to assist in the funding of the chronic kidney 21 disease and diabetes Registry as prescribed by law. 22

23 § 128. Annual Report

6

The Registry shall publish an annual statistical compilation that does not include
 identifying information showing the incidence of chronic kidney disease and diabetes in the
 Territory."

SECTION 2. The sum of \$250,000 is appropriated in the fiscal year ending September
30, 2024, from the General Fund of the Government of the Virgin Islands to the Department of
Health to create the Chronic Kidney Disease and Diabetes Registry and is available until
expended.

8

BILL SUMMARY

9 Section 1 creates title 19, chapter 6a. The new chapter is divided into eight sections.
10 Section 121 defines the terms used in the chapter; section 122 establishes the Registry; section
11 123 describes how and what entities must participate; section 124 discusses confidentiality;
12 section 125 addresses what disclosures are allowed; section 126 addresses liability; section 127
13 sets out penalties for violations of the mandates; and section 128 sets out the annual reporting
14 requirements. Section 2 appropriates funds to create the Registry.

15 23-0762/November 6, 2023/HLF